A Falsified Records Finding Is Not a Quality Problem. It Is a Coverage Problem

Reports in the first week of August 2026 carried a US Food and Drug Administration warning letter to Dabur India covering its Silvassa facility. Medical Dialogues reported it on 7 August 2026 as Dabur Faces USFDA Warning Letter Over Falsified Records, CGMP Violations at Silvassa Facility. Sahi, on 5 August 2026, set out the operative deadline: a response to the agency within 15 working days. Dabur's position, carried by Livemint on 6 August 2026, was that the India business is unaffected and the Silvassa plant continues to operate.

Three facts there are load bearing for an insurance desk, and each touches a policy condition. The finding names falsified records, not a mechanical failure or a contamination event, which puts it close to the dishonest, fraudulent and wilful act exclusions in almost every liability and recall wording sold in India. The 15 working day clock is the point at which a notifiable circumstance has plainly arisen. And a public statement about commercial impact, made before the regulator has responded, is a statement a shareholder body can later put in front of a board.

Most Indian exporters have never tested what their programme does with a finding of this kind. They have tested contamination. They have tested defect. Falsification is a different animal.

A US inspection outcome is not one event. It is a ladder, and the insurance consequences change at every rung. The August 2026 news flow made the range visible. Univest reported on 10 August 2026 that Emcure Pharmaceuticals' Sanand facility was cleared with VAI status, the middle outcome, while Dabur received a warning letter, the escalated one. Same regulator, same month, very different downstream exposure. The ladder, mapped against policy language:

1. Form 483 observations are issued at the close of an inspection and record what the investigator saw. There is no demand, no third party claim and no product action. On most D&O and product liability wordings this is a circumstance, not a claim.
2. Inspection classification follows. No Action Indicated closes the file. Voluntary Action Indicated, the Emcure outcome, means objectionable conditions were found but the agency will not act. Official Action Indicated triggers escalation.
3. The warning letter puts the agency's position in writing and demands a response inside the stated window. It identifies specific violations, names a facility, and creates a documented adverse regulatory position. Almost every wording's notification condition is engaged here.
4. Import alert is where money starts moving. Detention without physical examination stops shipments at the US border, and product already in the channel may be withdrawn. Recall costs, destruction costs and lost gross profit crystallise at this rung.
5. Consent decree or injunction is the far end: court supervised remediation on a multi-year cost base no annual policy was priced for.

Product recall wordings are built around two insured events. The first is accidental contamination, an unintentional error in manufacture, preparation, labelling or storage that renders the product unfit or unsafe. The second, on broader forms, is product defect or malicious tampering. Both are framed around something the insured did not intend.

Falsified batch records are intended by definition. Somebody wrote something that was not true. The moment the regulator's own document uses that language, the insurer's coverage counsel has a written finding of deliberate conduct.

The exclusions engaged, on Indian market forms and on the London forms most exporters buy for US exposure:

• Any dishonest, fraudulent, criminal or malicious act or omission by the insured or by anyone acting on its behalf.
• Any deliberate or wilful failure to comply with a statute, regulation or order of a regulatory authority.
• Any known defect, meaning a condition known to a senior officer before the policy period began.
• Governmental fines and penalties, usually excluded outright or heavily sublimited.

Three defensive points matter, and buyers should know which their wording gives them.

Severability. A well drafted exclusion applies only to the individual who committed the act and does not impute it to the innocent corporate insured. A poorly drafted one applies to the entity the moment any employee is implicated. On a data integrity finding, where the act is usually committed by an analyst or shift supervisor rather than the board, severability decides whether the loss is covered.

Final adjudication. Better conduct exclusions bite only on a final, non-appealable adjudication, and defence costs are advanced until then. Weaker ones bite on an allegation, a finding, or the insurer's own determination. A USFDA warning letter is a regulatory finding, not a judicial adjudication, and whether that distinction protects the insured turns on which version was bound.

Who counts as a senior officer. The known defect and prior knowledge conditions attach to named roles. If the definition reaches plant quality heads, a Form 483 in a QA folder is corporate knowledge.

Put those together and the stakes are clear. If the conduct exclusion applies on a finding rather than on a final adjudication, and severability is absent, a single data integrity citation can extinguish recall, product liability and D&O cover at the same time, off one regulatory document.

A recall policy is not a general purpose regulatory response cover. It pays a defined list of heads, each with its own trigger.

• Recall expense: communication, transport, warehousing, overtime and destruction, triggered by a recall the wording recognises.
• Lost gross profit: the fall in turnover attributable to the recalled product, usually over an indemnity period of 12 to 24 months. See business interruption for the gross profit mechanic.
• Rehabilitation: advertising and customer retention spend, almost always sublimited.
• Third party recall liability: the cost incurred by a customer who recalls their own finished product because the insured's ingredient was in it. For an exporter selling into a US supply chain this is often the largest exposure, and the one most frequently left off the schedule.

Three structural traps recur in the wordings Indian exporters hold.

The recall must be a recall. An import alert is a border action: goods are detained rather than recalled. Some wordings respond to government recall only where withdrawal of already distributed product has been ordered. Detention at the port, refused entry and the lost sales that follow may fall outside the insured event unless the form carries a government or regulatory action extension.

The trigger is usually safety, not compliance. Most forms require the product to be capable of causing bodily injury or property damage. A batch that is chemically fine but whose records cannot be relied on is a compliance failure, and if nobody can demonstrate the product is unsafe, the accidental contamination trigger is not met even though the commercial loss is real. A regulatory non-compliance or adverse publicity trigger closes that gap. Without one, the exporter carries it.

Territory and jurisdiction. Cover for a US recall requires the schedule to include USA and Canada for both territory and jurisdiction. Many India-issued policies carry a worldwide-excluding-USA-and-Canada basis at a lower premium, and the exclusion is discovered at claim stage. More on that trap in global product recall coverage for Indian exporters.

The warning letter that triggers the recall also creates the D&O exposure, and the two policies read the same document differently.

The director exposure comes from three directions. A listed company whose share price moves on the news faces shareholder action and, in India, class action under Section 245 of the Companies Act, 2013. The regulatory position attracts scrutiny of disclosure adequacy under the SEBI listing obligations, since a material regulatory action at a plant is generally price sensitive. Third is the oversight claim, an allegation that the board knew of repeated quality findings and failed to act. Commentary published by economy.ac on 19 August 2026, titled The Dark Side of the Pharmacy of the World, argued that chronic quality concerns persist across Indian pharmaceutical manufacturing despite rapid expansion. Sector commentary of that kind is what a plaintiff uses to argue a board was on notice.

Check the overlaps before a claim, not after:

• Definition of claim. Does it include a written demand from a regulatory authority, or only civil proceedings? If only proceedings, the cost of preparing the 15 working day response is not a covered defence cost.
• Investigation cover. Pre-claim inquiry cover, and whether it reaches a foreign regulator. A US agency action against an Indian issuer's facility is exactly where a narrow definition fails.
• Conduct exclusion alignment. If the recall policy and the D&O policy both decline on a dishonesty basis, the company is uninsured across the whole event. Aligning the two exclusions, and pushing both to final adjudication wording with full severability, is among the highest value renewal negotiations in this class. The mechanics are set out in directors and officers liability in Indian boardrooms.
• Order of payments. If the entity's own securities exposure exhausts the limit, individual directors are left without defence funding. Side A cover and an order of payments clause exist for this.

The product liability tower is exposed too, since a data integrity finding can be pleaded as evidence of negligent manufacture in a US injury suit years later, as described in Indian pharma's global product liability coverage.

The coverage dispute that follows an event like this rarely turns on the exclusion. It turns on the proposal form.

Every liability, D&O and recall proposal form in the Indian market asks a version of the same question: has the proposer, or any subsidiary, director or officer, been subject to any investigation, enquiry, inspection or action by a regulatory or governmental authority. The question is not limited to India, to concluded matters, or to actions the company considers material.

A Form 483 is an inspection finding by a governmental authority, so it answers that question. Yet at most exporters the 483 sits in a quality system the insurance team cannot access and has no reason to open, while the proposal form is completed by finance or the company secretary, answering honestly on the information they have, which is none.

The three year window in Section 45 of the Insurance Act, 1938 applies to life policies, and general insurers are not bound by it. A commercial liability insurer can avoid the contract for material non-disclosure at any point in the policy's life, subject to the common law of utmost good faith and the terms of the policy wording. The remedy is avoidance of the whole contract with premium returned, not a reduced payout.

The consequence is asymmetric in the worst way. The undisclosed item is a Form 483 that produced no loss. The avoided policy is the one covering the warning letter that did.

The fix is procedural and cheap. Before every renewal, the risk owner should obtain in writing from the quality head a list of every regulatory inspection at every site in the preceding 36 months and its outcome, covering all Form 483 observations, all inspection classifications and any foreign regulator correspondence. That list is disclosed in full and attached to the proposal. Over-disclosure has never voided a policy. Under-disclosure routinely does.

The structural failure at most exporters is that quality assurance and insurance sit in different reporting lines, use different systems and have no defined handover. A finding travels from the investigator to the plant QA head to the corporate quality function to the board. It does not travel to the broker. Six changes close that gap.

1. Name the trigger events in a written escalation protocol. Receipt of a Form 483, any inspection classification other than No Action Indicated, a warning letter or untitled letter, notification of an import alert, and any foreign regulator correspondence carrying a response deadline. Each is reported to the risk owner within 48 hours.
2. Notify circumstances, not just claims. On claims made D&O and product liability wordings, notifying a circumstance during the policy period locks the eventual claim to that policy year and its limit even if the claim arrives after renewal. It is the most valuable action available at the Form 483 stage and it costs nothing.
3. Read the notification clause before you need it. Some wordings require notice as soon as practicable, some within a fixed number of days, some in writing to a named address. A verbal mention to a servicing executive does not count.
4. Keep the 36 month regulatory register standing, updated at each event and used verbatim at renewal.
5. Test the wording against a falsification scenario. Ask the insurer in writing, before binding, how the recall trigger and the conduct exclusion respond to a data integrity finding with no demonstrated safety issue. That answer is more useful than the premium comparison.
6. Buy the extensions that match the failure mode. Regulatory action extension, adverse publicity trigger, third party recall liability, USA and Canada territory and jurisdiction, and a product withdrawal expense head.

Mandatory certification regimes at home create parallel triggers, covered in BIS quality control orders and product liability and recall insurance.

Dabur's Silvassa position may resolve without a recall, an import alert or a claim. That is not the point. The exporter beside it, carrying the same wording and the same disconnect between the quality folder and the proposal form, will not find out whether its programme responds until the day it needs it to.